Cancer Genomics Consults provides oncologists with a secure, GDPR-compliant portal for rapid analysis and consultation on complex cancer genomics cases, utilizing curated data from peer-reviewed literature and proprietary knowledge. This service addresses the challenge of oncologists' limited confidence and time in interpreting genomic data, enabling informed treatment decisions for patients.
Funding
$290.6K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Oncologists often lack the time and specialized expertise required to confidently interpret complex cancer genomic data from next-generation sequencing (NGS) reports. This can lead to delayed treatment decisions and potentially limit patient access to the most appropriate therapies. The increasing volume of new oncology publications further compounds this challenge.
Solution
Qnomx is an AI-powered platform designed to automate the interpretation of complex cancer genomic profiles, transforming tertiary NGS reports into concise, clinically actionable summaries. The platform streamlines genomic data interpretation by extracting key clinical insights through an interactive interface, reducing manual effort and interpretation time. Qnomx helps clinical laboratories and oncology clinics scale their operations, standardize reporting, and boost oncologist confidence in treatment decisions. The AI models are trained on curated datasets and trusted clinical sources, ensuring consistent and clinically relevant outputs.
Target Audience
Qnomx serves clinical laboratories seeking to reduce manual effort and scale operations, bioinformatics companies aiming to enhance the clinical actionability of their reports, and oncology clinics striving to make faster, more precise treatment decisions.
Features
- AI-driven interpretation of tertiary analysis NGS reports into concise clinical summaries
- Interactive interface for extracting key clinical insights
- Support for all metastatic cancer indications where NGS sequencing is used
- Integration via web interface or API without deep integration into LIMS, EMR, or EHR systems
- Proprietary AI models trained on curated datasets and trusted clinical sources (ClinVar, COSMIC, NCCN, OncoKB, HGMD, GENIE, CIVIC, and peer-reviewed literature)
- Ready-to-review clinical summaries in local languages
- Automated clinical analysis reduces manual effort, saving time and costs
- Standardized reporting ensures accuracy and consistency across reports